Organon & Co.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Product and Geographic Information
- Product and Geographic Information
Revenues of the Company’s products were as follows:
| Three Months Ended March 31, | ||||||
|---|---|---|---|---|---|---|
| 2026 | 2025 | |||||
| ($ in millions) | U.S. | Int’l | Total | U.S. | Int’l | Total |
| Women’s Health | ||||||
| Nexplanon/Implanon NXT | $127 | $74 | $201 | $176 | $72 | $248 |
| Follistim AQ | 21 | 39 | 61 | 35 | 34 | 69 |
| NuvaRing | 6 | 18 | 24 | 6 | 16 | 22 |
| Ganirelix Acetate Injection | 2 | 24 | 26 | 5 | 23 | 27 |
| Marvelon/Mercilon | — | 26 | 26 | — | 39 | 39 |
| Jada | 5 | — | 5 | 15 | — | 15 |
| Other Women’s Health (1) | 17 | 30 | 46 | 15 | 27 | 43 |
| General Medicines | ||||||
| Biosimilars | ||||||
| Renflexis | 42 | 15 | 57 | 44 | 12 | 57 |
| Hadlima | 51 | 16 | 67 | 33 | 14 | 47 |
| Ontruzant | 4 | 1 | 5 | 4 | 14 | 18 |
| Brenzys | — | 20 | 20 | — | 14 | 14 |
| Other Biosimilars (1) | 11 | 13 | 24 | — | 5 | 5 |
| Established Brands | ||||||
| Cardiovascular | ||||||
| Atozet | — | 85 | 85 | — | 77 | 77 |
| Zetia | 1 | 86 | 87 | 1 | 84 | 85 |
| Cozaar/Hyzaar | 2 | 55 | 57 | 2 | 53 | 55 |
| Vytorin | 1 | 20 | 21 | 1 | 22 | 23 |
| Rosuzet | — | 6 | 6 | — | 4 | 4 |
| Other Cardiovascular (1) | 1 | 27 | 28 | — | 30 | 30 |
| Respiratory | ||||||
| Singulair | 2 | 38 | 40 | 2 | 72 | 74 |
| Nasonex | — | 65 | 65 | — | 71 | 72 |
| Dulera | 23 | 12 | 35 | 34 | 10 | 43 |
| Clarinex | 1 | 30 | 31 | — | 34 | 34 |
| Other Respiratory (1) | 11 | 1 | 12 | 10 | 3 | 13 |
| Non-Opioid Pain, Bone and Dermatology | ||||||
| Arcoxia | — | 59 | 59 | — | 62 | 62 |
| Fosamax | — | 29 | 29 | 1 | 32 | 33 |
| Diprospan | — | 35 | 35 | — | 30 | 30 |
| Vtama | 23 | 2 | 25 | 20 | 4 | 24 |
| Other Non-Opioid Pain, Bone and Dermatology (1) | 3 | 65 | 68 | 4 | 65 | 68 |
| Other | ||||||
| Propecia | 1 | 28 | 30 | 1 | 24 | 26 |
| Emgality | — | 54 | 54 | — | 32 | 32 |
| Proscar | — | 26 | 26 | — | 24 | 24 |
| Other (1) | 3 | 85 | 87 | 3 | 76 | 78 |
| Other (2) | — | 18 | 18 | — | 22 | 22 |
| Revenues | $358 | $1,102 | $1,460 | $412 | $1,101 | $1,513 |
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.
(1) Includes sales of products not listed separately.
(2) Includes manufacturing sales to third parties.
-11-
Revenues by geographic area where derived are as follows:
| Three Months EndedMarch 31, | ||
|---|---|---|
| ($ in millions) | 2026 | 2025 |
| Europe and Canada | $412 | $376 |
| United States | 358 | 412 |
| Asia Pacific and Japan | 226 | 251 |
| China | 194 | 204 |
| Latin America, Middle East, Russia, and Africa | 247 | 240 |
| Other (1) | 23 | 30 |
| Revenues | $1,460 | $1,513 |
(1) Includes manufacturing sales to third parties.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.